Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD

Journal of the American Society of Nephrology

Volumn 26, Issue 10, 2015, Pages 2578-2587

  Umanath, Kausik ^a   Jalal, Diana I ^b   Greco, Barbara A ^c   Umeukeje, Ebele M ^d   Reisin, Efrain ^e   Manley, John ^f   Zeig, Steven ^g   Negoi, Dana G ^h   Hiremath, Anand N ⁱ   Blumenthal, Samuel S ^j   Sika, Mohammed ^d   Niecestro, Robert ^k   Koury, Mark J ^d   Ma, Khe Ni ^l   Greene, Tom ^l   Lewis, Julia B ^d   Dwyer, Jamie P ^d  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f Mountain Kidney and Hypertension Inc   (United States)

^g Pines Care Research Center   (United States)

^h UNIVERSITY OF VERMONT   (United States)

ⁱ Nephrology and Hypertension Clinic   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k University of Utah ^*  (United States)

^l UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CALCIUM ACETATE; FERRIC CITRATE; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; SEVELAMER CARBONATE; TRANSFERRIN; FERRIC ION;

ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HEPATOBILIARY DISEASE; HUMAN; HUMAN TISSUE; INFECTION COMPLICATION; IRON ABSORPTION; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRAVENOUS; ANEMIA; DRUG THERAPY, COMBINATION; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 84941178726     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014080842     Document Type: Article

References (36)

1. US Renal Data System: USRDS 2013 Annual Data Report: Atlas of End- Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
2. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[4 Suppl 3]: S1-S201, 2003.
3. Kidney Disease: ImprovingGlobalOutcomes (KDIGO)CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009.
4. KDOQINational Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. AmJ Kidney Dis 47[5 Suppl 3]: S16-S85, 2006.
5. KDOQI: KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. AmJ Kidney Dis 50: 471-530, 2007.
6. Liu SH, Chu HI: Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A.T. 10) and iron. Medicine (Baltimore) 22: 103-161, 1943.
7. Liu SH, Chu HI, Hsu HC, Chao HC, Cheu SH: Calcium and phosphorus metabolism in osteomalacia. XI. The pathogenetic role of pregnancy and relative importance of calcium and vitamin D supply. J Clin Invest 20: 255-271, 1941.
8. Umanath K, Niecestro R, Lewis J, Dwyer JP: Ferric citrate: A novel phosphate-binding agent. Expert Rev Endocrinol Metab 8: 13-19, 2013.
9. Sika M, Sinsakul MV, Niecestro RM, Chiang S: Prolonged use of ferric citrate (FC) as a phosphate binder reduces IV iron use in pts with ESRD. Presented at the American Society of Nephrology Renal Week, Denver, CO, November 16-21, 2010.
10. Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J; Collaborative Study Group: The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 121: c25-c29, 2012.
11. Lewis JB, SikaM, KouryMJ, Chuang P, Schulman G, SmithMT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP; forthe Collaborative Study Group: Ferric citrate controls phosphorus and delivers iron in patients on dialysis [published online ahead of print July 24, 2014]. J Am Soc Nephrol doi:ASN.2014020212.
12. Besarab A, Coyne DW: Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 6: 699-710, 2010.
13. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR: Intravenous iron versus erythropoiesis-stimulating agents: Friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis 16: 143-151, 2009.
14. Sargent JA, Acchiardo SR: Iron requirements in hemodialysis. Blood Purif 22: 112-123, 2004.
15. Skikne BS, Ahluwalia N, Fergusson B, Chonko A, Cook JD: Effects of erythropoietin therapy on iron absorption in chronic renal failure. J Lab Clin Med 135: 452-458, 2000.
16. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79: 299-305, 1998.
17. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996.
18. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48: 34-40, 1997.
19. Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25: 433-439, 1995.
20. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM; PA21 Study Group: A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86: 638-647, 2014.
21. Fuller DS, Pisoni RL, Bieber BA, Gillespie BW, Robinson BM: The DOPPS practice monitor for US dialysis care: Trends through December 2011. Am J Kidney Dis 61: 342-346, 2013.
22. Fishbane S, Mathew A, Vaziri ND: Iron toxicity: Relevance for dialysis patients. Am J Kidney Dis 29: 255-259, 2014.
23. Fleming RE, Ponka P: Iron overload in human disease. N Engl J Med 366: 348-359, 2012.
24. Ishida JH, Johansen KL: Iron and infection in hemodialysis patients. Semin Dial 27: 26-36, 2014.
25. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24: 1151- 1158, 2013.
26. Nairz M, Theurl I, Ludwiczek S, Theurl M, Mair SM, Fritsche G, Weiss G: The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell Microbiol 9: 2126-2140, 2007.
27. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE StudyGroup: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18: 975-984, 2007.
28. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19: 372-379, 2008.
29. Rodby R, Umanath K, Hsieh A, Niecestro R, Lewis J, Dwyer J, Group CS: Phosphorus binding with ferric citrate reduces erythropoiesis-stimulating agent usage and cost in patients with ESRD. Presented at the National Kidney Foundation Spring Clinical Meetings, Las Vegas, NV, April 22- 26, 2014.
30. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with lowhematocrit values in patients with cardiac diseasewho are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998.
31. Coyne DW: The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 82: 235-241, 2012.
32. A long-term safety extension trial of ferric citrate in patients with endstage renal disease (ESRD) on dialysis. Available at: https://clinicaltrials.gov/ct2/show/NCT01554982?term=NCT01554982&rank=1. Accessed August 29, 2014.
33. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP; Collaborative Study Group: Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int 17: 67-74, 2013.
34. Fresenius Medical Care North America: PhosLo Package Insert, Waltham, MA, Fresenius Medical Care North America, 2007.
35. Genzyme Corp.: Renvela Package Insert, Cambridge, MA, Genzyme Corp., 2010.
36. Dmitrienko A, Offen WW, Westfall PH: Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med 22: 2387-2400, 2003.